88 related articles for article (PubMed ID: 10438370)
1. Synergistic effect of interferon-gamma and mannosylated liposome-incorporated doxorubicin in the therapy of experimental visceral leishmaniasis.
Kole L; Das L; Das PK
J Infect Dis; 1999 Sep; 180(3):811-20. PubMed ID: 10438370
[TBL] [Abstract][Full Text] [Related]
2. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N; Mukherjee S; Das L; Das PK
Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
[TBL] [Abstract][Full Text] [Related]
3. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
Everlien H; Hockertz S
Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050
[TBL] [Abstract][Full Text] [Related]
4. Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis.
Murray HW; Moreira AL; Lu CM; DeVecchio JL; Matsuhashi M; Ma X; Heinzel FP
J Infect Dis; 2003 Aug; 188(3):458-64. PubMed ID: 12870129
[TBL] [Abstract][Full Text] [Related]
5. Targeting of parasite-specific immunoliposome-encapsulated doxorubicin in the treatment of experimental visceral leishmaniasis.
Mukherjee S; Das L; Kole L; Karmakar S; Datta N; Das PK
J Infect Dis; 2004 Mar; 189(6):1024-34. PubMed ID: 14999606
[TBL] [Abstract][Full Text] [Related]
6. Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice.
Dey R; Majumder N; Bhattacharyya Majumdar S; Bhattacharjee S; Banerjee S; Roy S; Majumdar S
Scand J Immunol; 2007 Dec; 66(6):671-83. PubMed ID: 18021365
[TBL] [Abstract][Full Text] [Related]
7. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
Mazumdar T; Anam K; Ali N
Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
[TBL] [Abstract][Full Text] [Related]
8. [TH1 response in the experimental infection with Trypanosoma cruzi].
Cardoni RL; Antúnez MI; Abrami AA
Medicina (B Aires); 1999; 59 Suppl 2():84-90. PubMed ID: 10668248
[TBL] [Abstract][Full Text] [Related]
9. Successful therapy of lethal murine visceral leishmaniasis with cystatin involves up-regulation of nitric oxide and a favorable T cell response.
Das L; Datta N; Bandyopadhyay S; Das PK
J Immunol; 2001 Mar; 166(6):4020-8. PubMed ID: 11238649
[TBL] [Abstract][Full Text] [Related]
10. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.
Bhowmick S; Ravindran R; Ali N
Vaccine; 2007 Aug; 25(35):6544-56. PubMed ID: 17655984
[TBL] [Abstract][Full Text] [Related]
11. Potential of doxorubicin as an antileishmanial agent.
Sett R; Basu N; Ghosh AK; Das PK
J Parasitol; 1992 Apr; 78(2):350-4. PubMed ID: 1556650
[TBL] [Abstract][Full Text] [Related]
12. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of neoglycoprotein-conjugated muramyl dipeptide against Leishmania donovani infection: the role of cytokines.
Sarkar K; Das PK
J Immunol; 1997 Jun; 158(11):5357-65. PubMed ID: 9164956
[TBL] [Abstract][Full Text] [Related]
14. Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma.
Murray HW; Stern JJ; Welte K; Rubin BY; Carriero SM; Nathan CF
J Immunol; 1987 Apr; 138(7):2290-7. PubMed ID: 3104456
[TBL] [Abstract][Full Text] [Related]
15. Macrophage-directed delivery of doxorubicin conjugated to neoglycoprotein using leishmaniasis as the model disease.
Sett R; Sarkar K; Das PK
J Infect Dis; 1993 Oct; 168(4):994-9. PubMed ID: 8376846
[TBL] [Abstract][Full Text] [Related]
16. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis.
Kaye PM; Curry AJ; Blackwell JM
J Immunol; 1991 Apr; 146(8):2763-70. PubMed ID: 1901883
[TBL] [Abstract][Full Text] [Related]
17. Targeting of piperine intercalated in mannose-coated liposomes in experimental leishmaniasis.
Raay B; Medda S; Mukhopadhyay S; Basu MK
Indian J Biochem Biophys; 1999 Aug; 36(4):248-51. PubMed ID: 10650726
[TBL] [Abstract][Full Text] [Related]
18. CXC chemokine-mediated protection against visceral leishmaniasis: involvement of the proinflammatory response.
Gupta G; Bhattacharjee S; Bhattacharyya S; Bhattacharya P; Adhikari A; Mukherjee A; Bhattacharyya Majumdar S; Majumdar S
J Infect Dis; 2009 Oct; 200(8):1300-10. PubMed ID: 19743920
[TBL] [Abstract][Full Text] [Related]
19. Cytokine interactions in experimental cutaneous leishmaniasis.
Solbach W; Röllinghoff M; Stenger S; Bogdan C
Behring Inst Mitt; 1991 Feb; (88):230-8. PubMed ID: 1904708
[TBL] [Abstract][Full Text] [Related]
20. Cytokine interactions in experimental cutaneous leishmaniasis. II. Endogenous tumor necrosis factor-alpha production by macrophages is induced by the synergistic action of interferon (IFN)-gamma and interleukin (IL) 4 and accounts for the antiparasitic effect mediated by IFN-gamma and IL 4.
Stenger S; Solbach W; Röllinghoff M; Bogdan C
Eur J Immunol; 1991 Jul; 21(7):1669-75. PubMed ID: 1905642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
